Integra LifeSciences Cuts 2026 Revenue Forecast After Cincinnati Flood Disruption

  • Integra LifeSciences expects Q3 2026 revenue of $410M–$412M, down from previous guidance due to Cincinnati facility flooding.
  • Full-year 2026 revenue guidance reduced from $1.654B–$1.695B to $1.634B–$1.654B.
  • Flooding disrupted operations at Cincinnati facility, impacting Q3 revenue by $7M and Q4 by $15M–$20M.
  • Company expects full manufacturing recovery at Cincinnati site by Q2 2027.
  • Insurance recoveries expected to mitigate substantial portion of earnings impact.

Integra LifeSciences' revised guidance highlights the vulnerability of medical technology supply chains to natural disasters. The company's ability to navigate this disruption will be a test of its operational resilience and insurance strategy. The broader industry is watching how Integra balances recovery efforts with maintaining commercial momentum.

Recovery Timeline
The pace at which Integra LifeSciences can restore full manufacturing operations at the Cincinnati facility will determine the extent of revenue and earnings impact.
Insurance Recoveries
Whether insurance recoveries will fully offset the financial impact of the flooding remains uncertain.
Commercial Execution
How effectively Integra can mitigate customer disruption and maintain market share during the recovery period.